Mupirocin for Staphylococcus Infections
Mupirocin 2% topical ointment is highly effective for minor staphylococcal skin infections like impetigo and secondarily infected lesions, applied 2-3 times daily for 5-10 days, and is the preferred agent for nasal decolonization of both MSSA and MRSA carriers before high-risk surgeries. 1, 2
Topical Treatment of Skin Infections
Indications and Application
- Mupirocin 2% ointment is FDA-approved for impetigo caused by Staphylococcus aureus and Streptococcus pyogenes 2
- Apply topically 2-3 times daily to affected areas 1, 3
- Treatment duration is typically 5-10 days, with clinical improvement expected within 3-5 days 1, 2
- Achieves >90% bacterial eradication and clinical cure rates in superficial skin infections 4, 3
Specific Clinical Scenarios
- Minor skin infections: impetigo, secondarily infected eczema, ulcers, or lacerations benefit from mupirocin monotherapy 1
- Pediatric use: Recommended for children with minor skin infections and secondarily infected lesions (safe from 2 months of age) 1, 2
- Cutaneous abscesses: Incision and drainage is the primary treatment; mupirocin alone is insufficient for abscess management 1
Important Limitations
- Not for mucosal surfaces - the polyethylene glycol base is inappropriate for intranasal use in the standard 2% ointment formulation 2
- Avoid in moderate-to-severe renal impairment due to polyethylene glycol absorption from open wounds 2
- Discontinue if no improvement within 3-5 days and reassess for alternative pathogens or resistance 2
Nasal Decolonization
Pre-operative Decolonization Protocol
- Mupirocin nasal ointment 2% applied twice daily for 5 days is the gold standard for MRSA and MSSA decolonization 5
- Timing: Complete decolonization 1-2 weeks before surgery; if interrupted, complete the course post-operatively 5
- Strongest evidence exists for cardiac and orthopedic surgery, where decolonization significantly reduces surgical site infections 5
- May be combined with chlorhexidine gluconate soap (40 mg/mL) for enhanced efficacy 5
Efficacy Data
- Eliminates nasal carriage in >95% of subjects within 2 days of starting treatment 4, 6
- Sustained effect: 71% remain free of S. aureus at 3 months post-treatment 7
- Reduces hand carriage: Intranasal application decreases hand colonization from 57.6% to 2.9% within 72 hours 7
- Effective against both methicillin-susceptible and methicillin-resistant strains 6, 8
Resistance Considerations
Global Resistance Patterns
- High-level mupirocin resistance (HLMuR): 8.1-8.5% globally, with increasing prevalence over time 9
- Low-level resistance: 9.7% among MRSA isolates 10
- Resistance is mediated by mupA gene (high-level) and ileS gene mutations (low-level) 10
Stewardship Principles
- Reserve mupirocin for appropriate indications to preserve efficacy 5, 9
- Monitor local resistance patterns in colonizing and infecting isolates 5
- Avoid prolonged or repeated courses to minimize resistance development 2, 9
- Do not use for systemic infections or as prophylaxis without documented colonization 1
Safety Profile
Adverse Effects
- Minimal side effects: Local reactions occur in <3% of patients 3
- Allergic reactions: Rare (0.7% in recent studies), manifesting as skin rash 11
- Intranasal use: May cause transient stinging and drying 2
- No systemic absorption when applied to intact skin, making systemic toxicity extremely rare 3
Special Populations
- Pregnancy Category B: No evidence of fetal harm in animal studies; use when clearly needed 2
- Nursing mothers: Unknown if excreted in breast milk; exercise caution 2
- Pediatric safety: Established for ages 2 months to 16 years 2
Common Pitfalls to Avoid
- Do not use standard 2% ointment intranasally - a calcium mupirocin formulation (Bactroban Nasal) is specifically designed for nasal use 2
- Do not rely on mupirocin alone for complicated skin infections requiring systemic antibiotics or surgical intervention 1
- Do not use in patients with polyethylene glycol sensitivity or significant renal impairment with open wounds 2
- Do not continue beyond 5 days without clinical improvement - consider alternative diagnoses or resistant organisms 2